A new Covid-19 vaccine from Novavax was found to be 89.3% effective in a clinical trial conducted in the UK and appears to offer protection against some variants of the coronavirus, the American ...

Novavax’s COVID-19 vaccine shown to be nearly 90% effective in UK clinical trial, provided a range of immunity against new variants ...

First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK ...

Novavax on Thursday said that its vaccine was 89% effective at preventing cases of COVID-19, based on results from a UK trial. In a trial in South Africa, the vaccine was far less effective ...

The UK government will collaborate with Novavax on phase 3 trials of its NVX-CoV2373 vaccine, according to a press release. Menu icon A vertical stack of three evenly spaced horizontal lines.

Coronavirus; UK study: Novavax Covid-19 vaccine works, but less so against variants. Published: Jan. 29, 2021, 6:42 a.m. Jan. 29, 2021, 6:42 a.m.

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy ...

Novavax said Thursday that final data from a trial in the United Kingdom shows its COVID-19 vaccine is almost 90 percent effective, but the vaccine was far less effective in a separate trial in ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novavax Inc. closed 60.86% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax's COVID-19 vaccine is effective against the British and South African variants, the Maryland biotech company said as the U.S. starts to detect more local cases of the highly transmissible.

A new Covid-19 vaccine from Novavax was found to be 89.3% effective in a clinical trial conducted in the UK and appears to offer protection against some variants of the coronavirus, the American ...